human IGF-I

Product Information
Species	Human
Sequence	The sequence of the first five N-terminal amino acids has been found to be Met-Phe-Pro-Ala-Met.
Purity	>98 % by SDS-PAGE analyses.90 % by RP-HPLC analyses
Endotoxin Level	The endotoxin level of Recombinant Human LR³-IGF-I is below 0.1 ng/ µg (1 IEU/ µg) of LR³-IGF-I.
Formulation	Lyophilized from a 0.2 µm filtered concentrated solution in 20 mM PB, pH 7.2.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Additional Information
Target Background	Human LR³ Insulin-like Growth Factor-I (LR³-IGF-I) is an 83 amino acid analog of human IGF-I comprising the complete human IGF-I sequence with the substitution of an Arg for the Glu at position 3 (hence R³), and a 13 amino acid extension peptide at the N-terminus. Scientists have engineered this analog with the express purpose of increasing biological activity. Human LR³-IGF-I is significantly more potent than human IGF-I in vitro. The enhanced potency is due to the markedly decreased binding of human LR³-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs. LR³ Insulin-like Growth Factor-I (LR³-IGF-I) (Media Grade), human, produced in E. coli, is a single, non-glycosylated, polypeptide chain containing 83 amino acids and having a molecular mass of 9,111 Da.